Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $143.18 USD
Change Today -0.04 / -0.03%
Volume 1.1M
BDX On Other Exchanges
Symbol
Exchange
New York
Frankfurt
As of 8:04 PM 07/2/15 All times are local (Market data is delayed by at least 15 minutes).

becton dickinson and co (BDX) Key Developments

BD Medical and Medtronic Collaborate to Introduce New Infusion Set

BD Medical and Medtronic announced a collaboration to introduce a new insulin pump infusion set with BD FlowSmart technology. An insulin infusion set delivers insulin from the pump to the body and is a critical part of the overall pump system. As part of the agreement, Medtronic will commercialize the infusion set, while BD will manufacture the product. This agreement represents an important collaboration between two diabetes device companies uniting to address unmet needs and improve infusion set options for people with diabetes using insulin pumps. The infusion set received both FDA clearance (April 2015) and Health Canada approval (January 2015) and is expected to be launched in 2016. The insulin infusion set with BD FlowSmart technology features a unique side-ported catheter designed to improve insulin flow, potentially reducing the number of flow interruptions – defined as a continuous rise in inline pressure lasting at least 30 minutes. Without triggering a pump occlusion alarm, these events are known as silent occlusions, and because pump users may be unaware of these lapses in insulin flow, they could lead to unexplained hyperglycemia in some people on pump therapy. This infusion set also features the smallest insertion needle (30 gauge) currently available, which is designed to reduce insertion pain.

BD Medical Releases Research on Infusion Sets That Represents a Potential Improvement in Insulin Pump Therapy for People with Diabetes

BD Medical released research on infusion sets that represents a potential improvement in insulin pump therapy for people with diabetes. The insulin infusion set with BD FlowSmart technology was developed in collaboration with JDRF and The Leona M. and Harry B. Helmsley Charitable Trust to enhance the use of insulin pumps and improve the treatment of type 1 diabetes. This infusion set recently received both FDA clearance and Health Canada approval and is expected to be launched in 2016. An application has been submitted for CE marking. 1071-P: Continuous Subcutaneous Insulin Infusion Sets: Reduced Flow Interruptions with a Novel Catheter Set- In this novel human study, researchers conducted a head-to-head comparison of the BD infusion set and commercially available infusion set, in 60 healthy subjects, who received two insertions of each infusion set followed by infusions of insulin diluent. The results showed that pressure rise events or silent occlusions were reduced by 75%, p = 0.03, from 10.2% to 2.6% of infusions. A silent occlusion is defined as a continuous rise in pressure of at least 30 minutes. Decreasing such flow interruptions may benefit patients by providing more consistent insulin delivery. 1088-P: Performance Qualification of Novel Continuous Subcutaneous Insulin Infusion Set Using Medical Imaging –This study used medical imaging techniques including MRI for the first time, to evaluate infusion catheter placement and fluid delivery patterns at various subcutaneous infusion sites. Studies conducted in both animals and people without diabetes assessed the performance of the BD side-ported catheter and other commercially-available catheters in their placement and delivery of insulin or insulin diluent. The images showed that the side port provides an additional flow pathway that may reduce occlusions and stabilize insulin flow. 1085-P: In Vivo Flow Evaluation and Correlation to Insulin Pharmacokinetics of Continuous Subcutaneous Insulin Infusion Sets – This study examined the flow performance of the BD infusion set compared with three commercial sets and their recommended pumps. The research, performed in non-diabetic Yorkshire swine, used flow pressure monitoring along with insulin-level analyses. The BD infusion set showed reductions of 88-95% in mean percent time of flow interruption as compared to the commercial catheter sets.

Becton, Dickinson and Company Presents at Goldman Sachs 36th Annual Global Healthcare Conference, Jun-10-2015 10:00 AM

Becton, Dickinson and Company Presents at Goldman Sachs 36th Annual Global Healthcare Conference, Jun-10-2015 10:00 AM. Venue: Terranea Resort, Rancho Palos Verdes, California, United States. Speakers: Christopher R. Reidy, Chief Financial Officer and Executive Vice President of Administration, Vincent A. Forlenza, Chairman, Chief Executive Officer, President and Chairman of Executive Committee.

Becton, Dickinson and Company Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 11:00 AM

Becton, Dickinson and Company Presents at Jefferies 2015 Global Healthcare Conference, Jun-01-2015 11:00 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States.

BDX Reportedly Seeks To Sell V.Mueller

Becton, Dickinson and Company (NYSE:BDX) is exploring a sale of its V. Mueller surgical instruments business after its $12.2 billion acquisition of CareFusion Corporation in March 2015, according to people familiar with the matter. JPMorgan Chase & Co to assist with a potential sale, which could fetch around $500 million, the sources said this week. They asked not to be named because the matter is private. BDX representative said the company is conducting a strategic review of all of its businesses and no decisions have been made. A spokeswoman for JPMorgan declined to comment. A sale would come as Becton Dickinson looks to shed non-core assets after its acquisition of CareFusion closed in March. Becton Dickinson is also expected to sell its respiratory business later this year, the sources added.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BDX:US $143.18 USD -0.04

BDX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astellas Pharma Inc ¥1,791 JPY +7.50
Avago Technologies Ltd $137.64 USD +2.14
Boston Scientific Corp $17.57 USD -0.23
Mylan NV $70.12 USD +0.42
Stryker Corp $95.76 USD -0.31
View Industry Companies
 

Industry Analysis

BDX

Industry Average

Valuation BDX Industry Range
Price/Earnings 26.3x
Price/Sales 3.3x
Price/Book 4.2x
Price/Cash Flow 27.8x
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BECTON DICKINSON AND CO, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.